Helocyte, Inc. was formed to develop novel immunotherapies for the prevention and treatment of cytomegalovirus (CMV), a common virus that is typically asymptomatic in healthy individuals, but can cause life-threatening disease in those with weakened or uneducated immune systems. The licensed immunotherapies were developed in the laboratory of Don J. Diamond, Ph.D., Chair of the Department of Experimental Therapeutics at City of Hope National Medical Center in Duarte, California. Under the terms of the agreement with City of Hope, Helocyte secured exclusive worldwide rights to two T-cell immunotherapeutic vaccines for controlling CMV in stem cell and solid organ transplant recipients. PepVax is an HLA-restricted vaccine for which we are currently enrolling a multi-center Phase II clinical study of CMV control in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Triplex is a universal vaccine for which we are currently enrolling a Phase II clinical study of CMV control in allogeneic HSCT recipients. Both programs are supported by grants from the National Cancer Institute. Helocyte further secured exclusive worldwide rights to Pentamer, a universal vaccine that induces a broad neutralizing antibody response to prevent transmission of CMV in utero (the most common congenital infection). Pentamer is currently undergoing pre-clinical development. Fortress Biotech owns >50% of Helocyte, Inc.
For more information, please visit www.helocyte.com.